Serum adiponectin levels and enzyme markers of liver dysfunction in diabetic and non-diabetic Caribbean subjects

British Journal of Biomedical Science

Volumn 63, Issue 3, 2006, Pages 117-122

  Ezenwaka, Chidum E ^a   Kalloo, R ^a   Uhlig, M ^b   Schwenk, R ^b   Eckel, J ^b  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Adiponectin; Diabetes mellitus; Liver function

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

EID: 33750297376     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2006.11732735     Document Type: Article

References (28)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. Ezenwaka CE. Metabolic control of type 2 diabetic patients commonly treated with sulphonylureas in a developing country. East Afr Med J 2003; 80 (4): 175-80.
3. Otieno CF, Kariuki M, Ng'ang'a L. Quality of glycaemic control in ambulatory diabetics at the out-patient clinic of Kenyatta National Hospital, Nairobi. East Afr Med J 2003; 80 (8): 406-10.
4. Erasmus RT, Sinha AK. Assessment of long-term glycaemic control in diabetic patients attending Port Moresby General Hospital. P N G Med J 1995; 38: 16-9.
5. Sidibe EH. Main complications of diabetes mellitus in Africa. Ann Med Interne (Paris) 2000; 151 (8): 624-8.
6. Ismail IS, Nazaimoon WM, Mohamad WB et al. Sociodemographic determinants of glycaemic control in young diabetic patients in peninsular Malaysia. Diabetes Res Clin Pract 2000; 47: 57-69.
7. Berg AH, Du Combs TPX, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-53.
8. Lopez-Bermejo A, Botas P, Funahashi T et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol 2004; 60: 256-63.
9. Fernandez-Real JM, Lopez-Bermejo A, Casamitjana Ricart W. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003; 88: 2714-8.
10. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-50.
11. Vozarova B, Stefan N, Lindsay RS et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 1889-95.
12. Sattar N, Scherbakova O, Ford I et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 2004; 53: 2855-60.
13. Hanley AJG, Williams K, Festa A et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004; 53: 2623-32.
14. Xu A, Wang Y, Keshaw H, Xu LY, Lam KSL, Cooper GJS. The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.
15. Michael MD, Kulkarni RN, Postic C et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6: 87-97.
16. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.
17. Zietz B, Herfarth H, Paul G et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 2003; 545 (2-3): 103-4.
18. Pellme F, Smith U, Funahashi T, Matsuzawa Y, Brekke H, Wiklund O. Circulating adiponectin levels are reduced in non-obese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 2003; 52: 1182-6.
19. Valsamakis G, Chetty R, McTernan PG, Al-Daghri NM, Barnett AH, Kumar S. Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol. Diabetes Obes Metab 2003; 25 (2): 131-5.
20. Ezenwaka CE, Kalloo R. Caribbean female patients with type 2 diabetes mellitus have lower serum levels of adiponectin than non-diabetic subjects. Neth J Med 2005; 63 (2): 64-9.
21. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet 1999; 354: 617-21.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
23. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipocyte specific protein, adiponectin in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
24. Degawa-Yamauchi M, Dilts JR, Bovenkerk JE, Saha C, Pratt JH, Considine RV. Lower serum adiponectin levels in African-American boys. Obes Res 2003; 11: 1384-90.
25. Hanley AJ, Connelly PW, Harris SB, Zinman B. Adiponectin in a native Canadian population experiencing rapid epidemiological transition. Diabetes Care 2003; 26: 3219-25.
26. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108: 1875-81.
27. Ohlson LO, Larsson B, Bjorntorp P, Eriksson H, Svardsudd K, Welin L. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus: thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 1988; 31: 798-805.
28. Tacke F, Wustefeld T, Horn R et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005; 42: 666-73.